Core Views - The report indicates that the yield rates of credit bonds have mostly risen, with the overall change ranging from -5 BP to 5 BP during the period from September 15 to September 21 [2] - The issuance scale of credit bonds has increased on a month-on-month basis, with corporate bonds maintaining zero issuance while other varieties saw an increase in issuance amounts [2] - The net financing amount of credit bonds has also increased, with corporate bonds and short-term financing bonds showing positive net financing, while company bonds, medium-term notes, and directional tools showed a decrease [2] Market Performance - The transaction amount of credit bonds in the secondary market has increased, with all varieties seeing a rise in transaction amounts [2] - The credit spreads have shown differentiation due to the varied performance of interest rate bonds, with short-term yields widening and long-term yields narrowing [2] - The report notes that the credit spreads for short-term bonds remain at historical lows, while long-term bonds have seen an increase in spreads, particularly for 5-year and 7-year AAA-rated bonds, which have reached around the 10% and 20% percentiles respectively, indicating high allocation value [2] Investment Strategy - The report suggests that despite the recent market fluctuations, the conditions for a comprehensive bear market in credit bonds are not sufficient, and yields are expected to enter a downward channel in the long term [2] - It recommends an active allocation strategy, particularly focusing on the trends in interest rate bonds and the coupon value of individual bonds [2] - The report emphasizes the importance of aligning investment strategies with market trends and adjusting trading strategies accordingly, while also monitoring the impact of growth-stabilizing policies on the bond market [2][3] Real Estate Market Insights - The report highlights that the central and local governments are actively optimizing real estate policies, which is expected to positively influence the stabilization of the real estate market [3] - It notes that the recovery of the real estate market will take time, and the sales recovery process will significantly impact bond valuations [3] - The focus for investment should be on high-quality central enterprises, state-owned enterprises, and well-guaranteed private enterprise bonds, with a potential for yield enhancement through longer durations [3] City Investment Bonds - The report states that the likelihood of default on city investment bonds is low under the current backdrop of stabilizing growth and preventing systemic risks [4] - It suggests that city investment bonds remain a key allocation target, although there may be valuation volatility risks during the transition of financing platforms [4] - Future opportunities may arise from the reform and transformation of "entity-type" financing platforms [4]

1. Report Industry Investment Rating There is no information provided regarding the industry investment rating in the documents. 2. Core Viewpoints of the Report - During the period from September 15 to September 21, the issuance guidance rates announced by the National Association of Financial Market Institutional Investors mostly increased, with an overall change range of -5 BP to 5 BP. The issuance scale of credit bonds increased month - on - month, while corporate bonds remained at zero issuance, and the issuance amounts of other varieties increased. The net financing of credit bonds increased month - on - month, with an increase in the net financing of corporate bonds and commercial paper, and a decrease in the net financing of corporate bonds, medium - term notes, and private placement notes. The trading volume of credit bonds in the secondary market increased month - on - month, and the yields of most credit bonds rose. Credit spreads showed a differentiated trend, with short - to - medium - term spreads narrowing and long - term spreads widening. [1][61] - On September 19, the Shanghai, Shenzhen, and Beijing Stock Exchanges issued a notice to optimize bond repurchase business. When the closing price of corporate bonds drops by 5% compared to the 20th trading day before, the repurchaser can repurchase bonds to stabilize market fluctuations. [2][64] - The central and local governments are actively optimizing real estate policies, which are playing a positive role in stabilizing the real estate market. For real estate bonds, investors with high - risk tolerance can consider early layout, focusing on high - quality bonds of central and state - owned enterprises and some high - quality private enterprises. [2][65][66] - Against the background of stable growth and prevention of systemic risks, the probability of urban investment bond defaults is low, and they can still be a key allocation variety. However, during the process of local financing platform clearance and transformation, some urban investment bonds may face valuation fluctuations. [3][66] 3. Summary According to the Directory 3.1 First - level Market Situation 3.1.1 Issuance and Maturity Scale - From September 15 to September 21, a total of 407 credit bonds were issued, with an issuance amount of 326.433 billion yuan, a month - on - month increase of 25.20%. The net financing of credit bonds was 88.638 billion yuan, an increase of 17.911 billion yuan month - on - month. [12] - Corporate bonds remained at zero issuance, with a net financing of - 4.241 billion yuan, an increase of 2.288 billion yuan month - on - month. The issuance amount of corporate bonds, medium - term notes, commercial paper, and private placement notes increased, but the net financing of corporate bonds, medium - term notes, and private placement notes decreased. [12] 3.1.2 Issuance Interest Rates - The issuance guidance rates announced by the National Association of Financial Market Institutional Investors mostly increased, with an overall change range of -5 BP to 5 BP. The rate changes varied by term and rating. [14] 3.2 Second - level Market Situation 3.2.1 Market Trading Volume - From September 15 to September 21, the total trading volume of credit bonds was 896.955 billion yuan, a month - on - month increase of 22.76%. The trading volumes of all varieties increased. [17] 3.2.2 Credit Spreads - For medium - and short - term notes, corporate bonds, and urban investment bonds, the credit spreads showed a differentiated trend, with 1 - year and 3 - year spreads narrowing and 5 - year and 7 - year spreads widening. [20][28][38] 3.2.3 Term Spreads and Rating Spreads - For AA+ medium - and short - term notes, the 3Y - 1Y term spread narrowed, while the 5Y - 3Y and 7Y - 3Y spreads widened. For rating spreads, the 3 - year (AA - )-(AAA) and (AA)-(AAA) spreads remained unchanged, and the (AA+)-(AAA) spread narrowed. [45] - For AA+ corporate bonds, the 3Y - 1Y, 5Y - 3Y, and 7Y - 3Y term spreads widened. For rating spreads, the 3 - year (AA - )-(AAA) and (AA)-(AAA) spreads widened, and the (AA+)-(AAA) spread remained unchanged. [50] - For AA+ urban investment bonds, the 3Y - 1Y term spread narrowed, while the 5Y - 3Y and 7Y - 3Y spreads widened. For rating spreads, the 3 - year (AA - )-(AAA) and (AA)-(AAA) spreads widened, and the (AA+)-(AAA) spread remained unchanged. [53] 3.3 Credit Rating Adjustments and Default Bond Statistics 3.3.1 Credit Rating Adjustment Statistics - From September 15 to September 21, the rating of one company was downgraded. [57] 3.3.2 Default and Extension Bond Statistics - Wuhan Contemporary Science & Technology Investment Co., Ltd.'s credit bond "H20 Technology 4" defaulted, with a default balance of 650 million yuan. There were no credit bond extensions during this period. [59][60] 3.4 Investment Views - In terms of absolute returns, the supply shortage and strong allocation demand support the strength of credit bonds. Although fluctuations are inevitable, the conditions for a full - scale bear market in credit bonds are still insufficient. In the long run, yields will enter a downward channel, and the strategy of increasing allocation during adjustments is still feasible. [1][61] - In terms of relative returns, due to the low historical levels of rating spreads, credit risk - taking is not effective at present. High - grade long - term bonds have certain advantages, and the duration can be appropriately extended, but the rhythm needs to be grasped. [1][61] - For real estate bonds, with the market gradually stabilizing, investors with high - risk tolerance can consider early layout, focusing on high - quality bonds of central and state - owned enterprises and some high - quality private enterprises. [2][66] - For urban investment bonds, they can be a key allocation variety, but attention should be paid to the valuation fluctuations during the clearance and transformation of local financing platforms. [3][66]

Market Overview - The major indices in the equity market showed mixed performance, with the ChiNext Index rising by 2.34% and the Shanghai 50 Index declining by 1.98% [2] - Among the 31 first-level industries, 13 experienced gains, with the top five performing industries being coal, electrical equipment, electronics, automobiles, and machinery [2] - The five industries with the largest declines were banking, non-ferrous metals, non-bank financials, steel, and agriculture [2] Public Fund Market - The scale of the Shanghai and Shenzhen ETF exceeded 5.1 trillion yuan [2] - In the past month, 14 actively managed equity funds were closed early [2] - Among equity funds, the average increase for equity-oriented funds was 0.63%, while fixed income plus funds saw an average decline of 0.08% with a positive return ratio of 41.65% [2] - Pure bond funds had an average increase of 0.03%, and pension target FOFs rose by an average of 0.54% [2] - QDII funds averaged an increase of 1.37%, with a positive return ratio of 81.14% [2] Fund Positioning - The industries with the highest increases in active equity fund positions were media, coal, and electrical equipment, while the largest decreases were in electronics, pharmaceuticals, and comprehensive sectors [3] - The overall positioning of active equity funds was measured at 77.69% as of September 19, 2025, a decrease of 0.51 percentage points from the previous period [3] ETF Market - The ETF market saw a net inflow of 13.612 billion yuan last week, with cross-border ETFs contributing a net inflow of 16.079 billion yuan [3] - Stock ETFs experienced a net inflow of 4.856 billion yuan [3] - The average daily trading volume in the ETF market reached 469.267 billion yuan, with an average daily turnover rate of 10.34% [3] - Major inflow themes included brokerages, robotics, and gold ETFs, while broad-based funds continued to see outflows, particularly from the Shanghai Stock Exchange STAR 50, CSI 300, and CSI A500 indices [3] Fund Issuance - A total of 31 new funds were issued last week, a decrease of 24 from the previous period, while 56 new funds were established, an increase of 17 [3] - The total amount raised by new funds was 70.735 billion yuan, an increase of 48.941 billion yuan from the previous period [3]

Macroeconomic and Strategy Research - The growth rate of general fiscal expenditure has shown a marginal slowdown, with public budget revenue for January to August 2025 at 148198 billion yuan, a year-on-year increase of 0.3%, while expenditure reached 179324 billion yuan, up 3.1% year-on-year [2][3] - Tax revenue has improved, with VAT showing a slight increase in growth rate, driven by manufacturing sales and high-tech industries, while corporate income tax has turned from decline to growth, indicating improved corporate profitability [3] - Public fiscal expenditure growth has slightly decreased, with social security and employment spending growing by 10%, while infrastructure spending has seen a significant decline [4] Fixed Income Research - The expectation for the central bank to restart bond purchases has increased, with a net injection of over 500 billion yuan in the open market during the reporting period [10][11] - The issuance of long-term government bonds has seen improved subscription sentiment, with a total issuance of 735.2 billion yuan during the period [10] - The bond market is currently viewed as a weak asset, with expectations for potential improvements depending on the liquidity situation and equity market performance [12] Industry Research - The pharmaceutical and biotechnology industry is focusing on overseas opportunities and innovative supply chains, with significant developments in drug approvals and partnerships among key companies [13][14] - The industry has experienced mixed performance, with the overall sector PE ratio at 31.43 times, indicating a premium over the broader market [14] - The upcoming European Society for Medical Oncology (ESMO) annual meeting is expected to highlight advancements in research from Chinese pharmaceutical companies, presenting investment opportunities in innovative drugs and related sectors [14][15]

Market Overview - In the recent trading period from September 12 to September 18, major indices showed mixed performance, with the Shanghai Composite Index declining by 1.13% and the ChiNext Index increasing by 1.38% [2] - The trading volume increased, with a total of 12.65 trillion yuan traded, averaging 2.53 trillion yuan per day, which is an increase of 278.79 billion yuan compared to the previous five trading days [2] Economic Data - From January to August, fixed asset investment grew by 0.5% year-on-year, reflecting a marginal decline of 1.1 percentage points [3] - The total retail sales of consumer goods from January to August increased by 4.6% year-on-year, which is a decrease of 0.2 percentage points compared to July [3] Policy Developments - Recently, the Ministry of Commerce and eight other departments issued measures to expand service consumption, proposing 19 measures focused on promoting consumption and expanding domestic demand [3] - The policy measures indicate a proactive approach to stimulate service consumption in light of the need to boost consumer demand [3] International Developments - On September 18, the Federal Reserve lowered the federal funds rate by 25 basis points, bringing the target range to 4.00% to 4.25%, aligning with market expectations [3] - The Fed's forecast for the policy rate in 2025 has been adjusted down to 3.6%, suggesting a potential for an additional 50 basis points of rate cuts within the year, indicating a trend towards further easing of overseas liquidity [3] Investment Strategy - The A-share market is exhibiting strong structural characteristics, with a focus on stabilizing the overall market while the technology-driven sectors are showing active performance [3] - The continuation of liquidity inflow will be crucial for maintaining the current structural market trends [3] Industry Focus - Investment opportunities are identified in the TMT sector due to the promotion of domestic alternatives in computing power and the upcoming peak season for smart terminal releases [4] - Other sectors with potential investment opportunities include pharmaceuticals, power equipment, non-ferrous metals, and machinery, driven by factors such as innovative drug exports, high demand for energy storage, and the anticipated mass production of robots [4]

Industry Research - In August, forklift sales reached 118,100 units, a year-on-year increase of 19.4% [2] - A significant increase in sales of aerial work vehicles was noted, with 490 units sold in August, representing a year-on-year growth of 88.5% [2] - The machinery equipment sector outperformed the Shanghai and Shenzhen 300 Index by 2.45 percentage points, with a 4.41% increase from September 10 to September 16, 2025 [2] - The current demand for engineering machinery is driven by ongoing projects in hydropower and urban renewal, alongside a reduction in tariff disturbances globally, enhancing the competitiveness of domestic machinery [2][3] - The industry maintains a "positive" outlook, with specific recommendations for companies such as Zoomlion (000157) and Haulotte Technology (002595) [3] Company Research: Heng Rui Pharmaceutical (600276) - Heng Rui Pharmaceutical is a leading pharmaceutical company in China, focusing on technological innovation and international expansion, with over 110 commercialized drugs, including 23 innovative new molecular entities [4][6] - The company is expected to receive approvals for approximately 47 innovative drugs and indications from 2025 to 2027, covering various fields such as oncology and metabolic diseases [6] - The company has made significant progress in international collaborations, enhancing its product strength and global recognition, with over 20 overseas clinical trials initiated [6] - The forecasted net profit for Heng Rui Pharmaceutical from 2025 to 2027 is projected to be 8.05 billion, 9.88 billion, and 11.71 billion yuan respectively, with an EPS of 1.21, 1.49, and 1.76 yuan per share [7]

Macro and Strategy Research - The economic data for August 2025 shows that the industrial added value increased by 5.2% year-on-year, lower than the expected 5.6% and previous value of 5.7% [4] - The retail sales of consumer goods grew by 3.4% year-on-year, below the expected 3.8% and previous value of 3.7% [4] - Fixed asset investment cumulative year-on-year growth was only 0.5%, significantly lower than the expected 1.3% and previous value of 1.6% [4] Consumption Trends - The growth rate of retail sales in August was weaker than market expectations due to diminishing policy effects and declining consumer willingness [5] - Restaurant income saw a recovery due to summer outings and platform subsidies, but retail sales growth slowed down by 0.4 percentage points to 3.6% [5] - The automotive and jewelry sectors performed relatively well, but overall consumption growth faces challenges due to rising baselines and employment expectations [5] Investment Expectations - Fixed asset investment growth has declined for five consecutive months, with manufacturing investment dropping by 1.0 percentage points to -1.3% year-on-year [6] - Infrastructure investment growth fell by 4.4 percentage points to -6.4% due to adverse weather conditions [6] - Real estate investment saw a significant decline of 2.5 percentage points to -19.5%, with new construction and completion rates also decreasing [6] Fixed Income Research - Credit bond yields have risen across the board, reaching yearly highs, while credit spreads have shown differentiation among short- and medium-term notes [8] - The net financing amount for credit bonds increased, with company bonds and medium-term notes showing positive net financing [8] - The overall market sentiment remains cautious, with a focus on adjusting strategies in response to yield fluctuations [8] Fund Research - The equity market indices all rose, with the Sci-Tech 50 index increasing by 5.48% [11] - The average return for equity funds was 2.28%, while fixed income funds showed a slight decline [11] - A total of 55 new funds were issued, raising 217.94 billion, which is a decrease from the previous period [12] Industry Research on Solid-State Batteries - Solid-state batteries are seen as a key trend in battery technology, with sulfide electrolytes being the main research focus [14] - The demand for lithium, germanium, zirconium, titanium, and lanthanum is expected to rise significantly due to solid-state battery development [16] - Companies with upstream resource advantages and strong R&D capabilities in solid-state battery materials are recommended for investment [17]

Macro and Strategy Research - In August, social financing increased by nearly 500 billion yuan year-on-year, primarily due to a decrease in government bond financing, which fell by 251.9 billion yuan year-on-year, marking the first time it became a drag on social financing this year [2] - The weak performance of credit financing is attributed to low demand from the real economy, particularly in the context of capacity optimization, leading to low corporate financing willingness [2] - Short-term loans for enterprises showed relative improvement, transitioning from a net withdrawal in August 2024 to net financing in August 2025, likely due to rising bond market yields and increased financing costs [2] - M1 growth rate rebounded to 6.0% in August, influenced by the cessation of "manual interest compensation" and accelerated fiscal fund disbursement [3] - Overall, August financial data reflects insufficient financing demand, with notable changes including weakened government bond financing support and a shift of resident deposits towards non-bank financial institutions [3] Industry Research - The listing of double glue paper futures is expected to improve profitability for packaging paper companies, as it allows for better cost control and revenue stability through a closed-loop management of price risks from raw materials to finished products [6] - Recent price adjustments in white cardboard and corrugated paper indicate a new round of price increases, with prices for corrugated paper, boxboard, and whiteboard paper rising by 50 yuan per ton week-on-week [6] - The light industry manufacturing sector outperformed the CSI 300 index by 0.50 percentage points from September 8 to September 12, while the textile and apparel sector underperformed by 0.71 percentage points [6] - The upcoming release of 690 billion yuan in national subsidy funds is expected to support domestic demand in the home furnishing sector, while the Federal Reserve's anticipated interest rate cuts may stimulate overseas demand [7] - The strategy maintains a "neutral" rating for the light industry manufacturing and textile apparel sectors, with specific stocks like Oppein Home (603833) and Sophia (002572) rated as "buy" [6][7]

Macro and Strategy Research - The US labor market shows signs of weakness, with August non-farm employment data falling short of expectations and previous months' figures revised downwards, indicating a potential deterioration trend [3][4] - In Europe, the European Central Bank remains confident about future inflation and economic growth, with market expectations for a rate cut before mid-2026 dropping below 50% [4] - Domestic exports in China have declined year-on-year due to high base effects from last year, but exports to non-US regions continue to perform better, which may influence future growth [4][7] - The PPI in China is expected to show a low recovery in September, while CPI growth is significantly affected by food and energy prices [4][7] Fixed Income Research - The yield curve has steepened, with the bond market under pressure due to a strong equity market and adjustments in redemption fees affecting market sentiment [8][9] - In the primary market, the issuance of interest rate bonds totaled 74, with a net financing amount of 45.2 billion yuan, indicating a gradual decrease in supply pressure [7][9] - The central bank's actions, including potential 14-day reverse repos, will be crucial in determining the liquidity situation in the market [9] Industry Research - Chinese pharmaceutical companies showcased impressive research results at the World Lung Cancer Conference (WCLC), highlighting the strength of domestic innovation [10][12] - Hengrui Medicine has signed a licensing agreement for the HRS-1893 project and has received drug registration approval, indicating its ongoing expansion efforts [11][12] - The overall performance of the pharmaceutical and biotechnology sector has been positive, with the industry index showing a 1.76% increase, outperforming other sectors [11][12] - The upcoming China Clinical Oncology Society (CSCO) annual meeting and the European Society for Medical Oncology (ESMO) conference are expected to provide further insights into the industry's development [12]

Investment Rating - The industry rating is "Positive" for the next 12 months, expecting a growth rate exceeding 10% relative to the CSI 300 index [67][79]. Core Insights - The report highlights the impressive research outcomes of Chinese pharmaceutical companies showcased at the 2025 World Lung Cancer Conference (WCLC), emphasizing the strength of innovation in the sector. It also notes that Heng Rui has further advanced its overseas licensing strategy through the NewCo model [9][67]. - The report suggests continuous monitoring of the R&D progress of Chinese pharmaceutical companies, particularly in innovative drugs and related industrial chains, benefiting from optimized procurement rules in the pharmaceutical and medical device sectors, as well as the recovery of traditional Chinese medicine and medical services due to domestic demand [9][67]. Industry News - Bai Li Tian Heng's dual-target ADC for EGFR/HER3 has shown promising results at WCLC, with a 100% overall response rate in a study involving 154 patients [18]. - BeiGene presented the latest findings from its RATIONALE studies at WCLC, demonstrating significant survival benefits for its drug in treating non-small cell lung cancer [19]. - Kangfang Biotech updated data from its HARMONi study, showing improved overall survival rates, particularly in North America [20]. Company Announcements - Heng Rui Pharma signed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and potential milestone payments totaling up to $1.013 billion [35]. - The new drug application for KN026 by CSPC has been accepted by the National Medical Products Administration (NMPA) [39]. - Junshi Biosciences reported positive results from its Phase III clinical trial for an anti-IL-17A monoclonal antibody [40]. Market Review - The Shanghai Composite Index rose by 2.91%, while the Shenzhen Component Index increased by 7.11%. The pharmaceutical and biological sector saw a 1.76% increase, with most sub-sectors showing positive performance [53][57]. - As of September 11, 2025, the TTM P/E ratio for the pharmaceutical and biological industry was 31.56, with a valuation premium of 148% relative to the CSI 300 [57]. Weekly Strategy - The report recommends focusing on investment opportunities in innovative drugs and medical devices, as well as sectors benefiting from domestic demand recovery, while maintaining a "Positive" industry rating [67].